Literature DB >> 32619895

A coup d'état by NDM-producing Klebsiella pneumoniae overthrows the major bacterial population during KPC-directed therapy.

Justin R Lenhard1, Amisha P Rana2, Eric Wenzler2, Yanqin Huang2, Barry N Kreiswirth3, Liang Chen3, Zackery P Bulman4.   

Abstract

The objective of this study was to utilize a co-culture hollow-fiber infection model (HFIM) to characterize the interplay between a small, difficult-to-detect, New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae (NDM-Kp) minor population and a larger K. pneumoniae carbapenemase (KPC)-producing K. pneumoniae population in the presence of KPC-directed antibacterial therapy. Selective plating onto agar with ceftazidime-avibactam was used to track the density of the NDM-Kp population. Susceptibility testing and the Verigene System failed to identify the small initial NDM-Kp population. However, a ceftazidime-avibactam Etest detected resistant colonies that were confirmed to be NDM-Kp. In the HFIM, all of the investigated drug regimens caused regrowth within 24 h and resulted in >109 CFU/mL of NDM-Kp. Our study demonstrates that the HFIM is a powerful tool for studying the population dynamics of multiple pathogens during antimicrobial exposure and also highlights that difficult-to-detect minor populations of drug-resistant bacteria may cause treatment failure without appropriate antibacterial therapy.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ceftazidime-avibactam; Hollow fiber infection model; Klebsiella pneumoniae; Polymicrobial; Rapid diagnostics

Mesh:

Substances:

Year:  2020        PMID: 32619895      PMCID: PMC7423700          DOI: 10.1016/j.diagmicrobio.2020.115080

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  21 in total

1.  Antibiotic-resistant sub-populations of the pathogenic bacterium Staphylococcus aureus confer population-wide resistance.

Authors:  Ruth C Massey; Sharon J Peacock
Journal:  Curr Biol       Date:  2002-10-15       Impact factor: 10.834

2.  Synergistic interactions of Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro wound model.

Authors:  Stephanie DeLeon; Allie Clinton; Haley Fowler; Jake Everett; Alexander R Horswill; Kendra P Rumbaugh
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

3.  High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Authors:  Justin R Lenhard; Jürgen B Bulitta; Terry D Connell; Natalie King-Lyons; Cornelia B Landersdorfer; Soon-Ee Cheah; Visanu Thamlikitkul; Beom Soo Shin; Gauri Rao; Patricia N Holden; Thomas J Walsh; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2016-09-15       Impact factor: 5.790

4.  Rising rates of carbapenem-resistant enterobacteriaceae in community hospitals: a mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States.

Authors:  Joshua T Thaden; Sarah S Lewis; Kevin C Hazen; Kirk Huslage; Vance G Fowler; Rebekah W Moehring; Luke F Chen; Constance D Jones; Zack S Moore; Daniel J Sexton; Deverick J Anderson
Journal:  Infect Control Hosp Epidemiol       Date:  2014-06-20       Impact factor: 3.254

5.  New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae.

Authors:  Zackery P Bulman; Michael J Satlin; Liang Chen; Barry N Kreiswirth; Beom Soo Shin; Thomas J Walsh; Patricia N Holden; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

6.  Polymicrobial and monomicrobial bacteraemic urinary tract infection.

Authors:  Y Siegman-Igra; T Kulka; D Schwartz; N Konforti
Journal:  J Hosp Infect       Date:  1994-09       Impact factor: 3.926

7.  Genetic features of blaNDM-1-positive Enterobacteriaceae.

Authors:  Laurent Poirel; Laurent Dortet; Sandrine Bernabeu; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

8.  Therapeutic Drug Monitoring of Gentamicin Peak Concentrations in Critically Ill Patients.

Authors:  Caspar J Hodiamont; Julie M Janssen; Menno D de Jong; Ron A Mathôt; Nicole P Juffermans; Reinier M van Hest
Journal:  Ther Drug Monit       Date:  2017-10       Impact factor: 3.681

9.  Bacterial brothers in arms: cooperation of Staphylococcus aureus and Pseudomonas aeruginosa during antimicrobial exposure.

Authors:  Justin R Lenhard; Nicholas M Smith; Christine D Quach; Tuan Q Nguyen; Linh H Doan; Jeanette Chau
Journal:  J Antimicrob Chemother       Date:  2019-09-01       Impact factor: 5.790

10.  Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. Scandinavian Amikacin Once Daily Study Group.

Authors:  R Maller; H Ahrne; C Holmen; I Lausen; L E Nilsson; J Smedjegård
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

View more
  1 in total

1.  Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae.

Authors:  Yanqin Huang; Karol Sokolowski; Amisha Rana; Nidhi Singh; Jiping Wang; Ke Chen; Yinzhi Lang; Jieqiang Zhou; Neera Kadiyala; Fiorella Krapp; Egon A Ozer; Alan R Hauser; Jian Li; Jürgen B Bulitta; Zackery P Bulman
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.